THE Therapeutic Goods Administration (TGA) has approved Nicorette QuickMist oral spray for the treatment of nicotine vaping dependence, becoming the first product in Australia to be approved for this purpose.
Already approved for smoking cessation, the indication has now expanded to include vaping cessation.
This marks a significant step forward in providing accessible, evidence-based support for people looking to manage cravings, withdrawal symptoms, and break their dependence on nicotine, said manufacturer Kenvue.
"Quitting nicotine vaping can be a challenging journey, particularly without the option of an approved pharmacotherapy," said Nadine Saraceno, Director of Regulatory Affairs Australia and New Zealand at Kenvue.
"Our clinical trial demonstrated that Nicorette QuickMist, our fastest acting NRT format, helped reduce nicotine cravings by at least 50% in eight out of 10 nicotine vape users after just one dose," she explained.
The spray can help by interrupting the cycle of withdrawal, allowing for a gradual reduction in daily nicotine intake until the user can quit completely.
It works by delivering small doses of nicotine through the mouth lining, helping to ease withdrawal symptoms and relieve vaping cravings from 30 seconds and up to two hours after dosing.
"We are proud to offer the first approved option for the relief of nicotine vaping cravings, with the potential to support thousands of Australians in overcoming their dependence on nicotine vaping," Saraceno concluded.
Read about the trial HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Aug 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Aug 25
